Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBT Margin (2021 - 2025)

Historic EBT Margin for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 4248.45%.

  • Aligos Therapeutics' EBT Margin fell 27150100.0% to 4248.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 3284.45%, marking a year-over-year decrease of 17551500.0%. This contributed to the annual value of 3624.48% for FY2024, which is 26940500.0% down from last year.
  • Per Aligos Therapeutics' latest filing, its EBT Margin stood at 4248.45% for Q3 2025, which was down 27150100.0% from 1624.66% recorded in Q2 2025.
  • Aligos Therapeutics' 5-year EBT Margin high stood at 13868.49% for Q1 2025, and its period low was 13551.65% during Q4 2024.
  • Moreover, its 5-year median value for EBT Margin was 1389.85% (2023), whereas its average is 1870.78%.
  • In the last 5 years, Aligos Therapeutics' EBT Margin plummeted by -121618000bps in 2024 and then soared by 188885200bps in 2025.
  • Aligos Therapeutics' EBT Margin (Quarter) stood at 10292.1% in 2021, then skyrocketed by 94bps to 617.39% in 2022, then crashed by -125bps to 1389.85% in 2023, then plummeted by -875bps to 13551.65% in 2024, then soared by 69bps to 4248.45% in 2025.
  • Its last three reported values are 4248.45% in Q3 2025, 1624.66% for Q2 2025, and 13868.49% during Q1 2025.